Efficacy and safety of docetaxol, pemetrexed and EGFR-TKIs as second-line treatment for patients with advanced non-small-cell lung cancer.
- Author:
Ru-xia ZHANG
1
;
Dong-yan CAI
;
Xiao-hong WU
;
Dong HUA
Author Information
- Publication Type:Journal Article
- MeSH: Adenocarcinoma; drug therapy; pathology; Aged; Antimetabolites, Antineoplastic; therapeutic use; Antineoplastic Agents; therapeutic use; Carcinoma, Non-Small-Cell Lung; drug therapy; pathology; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glutamates; therapeutic use; Guanine; analogs & derivatives; therapeutic use; Humans; Lung Neoplasms; drug therapy; pathology; Male; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; therapeutic use; Quinazolines; therapeutic use; Receptor, Epidermal Growth Factor; antagonists & inhibitors; therapeutic use; Survival Rate; Taxoids; therapeutic use
- From: Chinese Journal of Oncology 2012;34(11):869-872
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the efficacy and safety of docetaxol, pemetrexed and EGFR-TKIs in the second-line treatment for patients with advanced non-small cell lung cancer.
METHODSThe clinical data of 170 patients with advanced non-small cell lung cancer who failed standard first-line chemotherapy were reviewed. Those who received docetaxol as second-line therapy were designated as group A (n = 60), those who received pemetrexed as second-line therapy were designated as group B (n = 49), and those who received EGFR-TKIs as second-line therapy were designated as group C (n = 61). PFS and MST were estimated by Kaplan-Meier method and the differences between groups were compared by log-rank test.
RESULTSThe response rate in the groups A, B and C group was 15.0% (9/60), 24.5% (12/49) and 36.1% (22/61), respectively. The PFS after second-line therapy in the groups A, B and C was 5.49 months (95%CI: 4.03 - 6.95 months), 5.42 months (95%CI: 4.23 - 6.60 months) and 9.31 months (95%CI: 6.88 - 11.73 months), respectively (P = 0.045). The MST after second-line therapy in the groups A, B and C was 14.89 months (95%CI: 11.23 - 18.55 months), 15.81 months (95%CI: 12.11 - 19.52 months) and 17.47 months (95%CI: 13.38 - 21.56 months), respectively (P = 0.574). Regression analysis showed that the performance status score (PS) and response for second-line treatment are independent prognostic factors in each sub-group, and pathological type is an independent prognostic factor in the group C (P = 0.003).
CONCLUSIONSThe safety of the three drugs used as second-line treatment for patients with advanced non-small-cell lung cancer, who failed standard first-line chemotherapy, is comparable, but the EGFR-TKIs group has the highest response rate, and the EGFR-TKIs group has the longest PFS with a statistically significant difference, while there is no significant difference in MST among the three groups. When patients receive second-line treatment, the performance status < 2 and the response rate for second-line treatment are independent prognostic factors. Furthermore, pathological type (adenocarcinoma) is also an independent prognostic factor for EGFR-TKIs as second-line treatment.
